BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25530565)

  • 1. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.
    Souza Melo CP; Campos CB; Dutra ÁP; Neto JC; Fenelon AJ; Neto AH; Carbone EK; Pianovski MA; Ferreira AC; Assumpcão JG
    Leuk Res; 2015 Feb; 39(2):131-7. PubMed ID: 25530565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
    Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
    Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological & molecular profile of acute myelogenous leukaemia in India.
    Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
    Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
    Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
    Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
    Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
    Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
    Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
    Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
    Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
    Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FLT3 internal tandem duplication in patients with acute promyelocytic leukemia].
    Zhu YM; Liu YF; Zhang SJ; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):371-4. PubMed ID: 17939400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes.
    Albano F; Mestice A; Pannunzio A; Lanza F; Martino B; Pastore D; Ferrara F; Carluccio P; Nobile F; Castoldi G; Liso V; Specchia G
    Haematologica; 2006 Mar; 91(3):311-6. PubMed ID: 16531253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
    Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
    Gale RE; Hills R; Pizzey AR; Kottaridis PD; Swirsky D; Gilkes AF; Nugent E; Mills KI; Wheatley K; Solomon E; Burnett AK; Linch DC; Grimwade D;
    Blood; 2005 Dec; 106(12):3768-76. PubMed ID: 16105978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
    Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
    Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variant acute promyelocytic leukemia translocation (15;17) originating from two subsequent balanced translocations involving the same chromosomes 15 and 17 while preserving the PML/RARA fusion.
    Tirado CA; Jahn JA; Scheerle J; Eid M; Meister RJ; Christie RJ; Croft CD; Wallingford S; Heritage DW; Mowrey PN; Meloni-Ehrig AM
    Cancer Genet Cytogenet; 2005 Aug; 161(1):70-3. PubMed ID: 16080960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study.
    Lilakos K; Viniou NA; Mavrogianni D; Vassilakopoulos TP; Dimopoulou MN; Plata E; Angelopoulou MK; Variami E; Stavrogianni N; Liapi D; Xilouri I; Galanopoulos A; Ageloudi M; Panayiotidis P; Voulgarelis M; Rombos J; Meletis J; Yataganas X; Pangalis GA
    Anticancer Res; 2006; 26(2A):1201-7. PubMed ID: 16619525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.